respiratory
GAP Index for Idiopathic Pulmonary Fibrosis
Gender, Age, Physiology (GAP) index predicts 1, 2, and 3-year mortality in idiopathic pulmonary fibrosis (IPF) using clinical and physiological variables.
References
- Ley B et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–691.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Nitric Oxide (Inhaled — iNO) · Selective Pulmonary Vasodilator
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
- Community-Acquired Pneumonia (CURB-65) · BTS 2009 / NICE NG138
- Acute Pulmonary Embolism · BTS 2003 / ESC 2019
- Pleural Effusion Assessment · BTS 2010
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.